Method for preparing drug intermediate pyrimido [4, 5-b] quinoline derivative under catalysis of eutectic solvent

By using a low eutectic solvent catalyst in the preparation of pyrimidine[4,5-b]quinoline derivatives, the complex catalyst preparation and environmental pollution problems are solved, and an efficient and economical production process is achieved, which is suitable for industrial applications.

CN119019390APending Publication Date: 2024-11-26NANJING SUYIXIN PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411135012.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the prior art, the catalyst preparation is complex, difficult to biodegradable, poor economical, and large amount of reaction solvents, resulting in serious environmental pollution, especially in the preparation process of pyrimidine [4,5-b]quinoline derivatives.

Method used

Using eutectic solvent as a catalyst and reaction solvent, the three-component reaction of aromatic aldehyde, 6-aminoureacil and 1,3-cyclohexanedione are prepared by catalyzing the three-component reaction of caprolactam and p-toluenesulfonic acid. and [4,5-b]quinoline derivatives, simplify the catalyst preparation process and increase the number of cycles.

Benefits of technology

It realizes simple preparation and multiple recycling of catalysts, reduces environmental pollution, improves production efficiency and economy, and simplifies the separation and purification process of products, which is suitable for industrial large-scale continuous production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019390A_ABST
    Figure CN119019390A_ABST
Patent Text Reader

Abstract

The invention relates to the field of preparation of medical intermediates, and particularly discloses a method for preparing a drug intermediate pyrimido [4, 5-b] quinoline derivative under the catalysis of a deep-eutectic solvent, which comprises the following steps: by taking aromatic aldehyde, 6-aminouracil derivative and 1, 3-cyclohexanedione derivative as reaction raw materials, and taking the deep-eutectic solvent as a catalyst, reacting at the temperature of 60-80 DEG C to obtain the pyrimido [4, 5-b] quinoline derivative. And preparing under a heating condition. The method has the advantages that the catalyst is simple and convenient to prepare, can be recycled for many times, can be regenerated, and is economical, efficient, small in environmental pollution and the like. In addition, the product pyrimido [4, 5-b] quinolinone derivative is easy to separate and simple to purify, and industrial large-scale continuous production can be easily realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a method for preparing a derivative, in particular to a method for preparing a drug intermediate pyrimido[4,5-b]quinoline derivative by catalysis of a low eutectic solvent, and belongs to the field of preparation of drug intermediates. Background Art

[0002] Heterocyclic compounds are widely distributed in nature. Many important natural drugs, synthetic drugs and highly effective and low-toxic pesticides contain heterocyclic compound structures. Biologically active nitrogen-containing heterocyclic compounds have always been an important field in pharmaceutical chemistry research, and many nitrogen-containing heterocyclic compounds have been developed into new pharmaceutical products. As an important nitrogen-containing heterocyclic compound and pharmaceutical intermediate, pyrimidine and quinoline compounds occupy a very important position in pharmaceutical research due to their simple structure, broad-spectrum, high-efficiency and low-toxic biological activity, and show significant antibacterial, anti-inflammatory, anti-tumor, anti-allergic, analgesic and antioxidant properties. Therefore, the synthesis of such compounds has attracted widespread attention from chemists and pharmacists.

[0003] Multicomponent reaction refers to a one-step chemical reaction of three or more reactants, and the generated product contains all the starting materials. It has the characteristics of simple operation, high resource utilization and high atom economy. At present, multicomponent reaction has been applied in the preparation process of pyrimidoquinoline derivatives. For example, Maya Shankar Singh et al. used a catalytic system composed of p-toluenesulfonic acid as a catalyst and water as a reaction solvent, which can effectively catalyze the three-component reaction of aldehydes, 6-amino-1,3-dimethyluracil and 1,3-cyclohexanedione derivatives to prepare pyrimido[4,5-b]quinolinone derivatives (Anefficient one-pot three-component synthesis of functionalized pyrimido[4,5-b]quinolines and indeno fusedpyrido[2,3-d]pyrimidines inwater[J], Tetrahedron Letters, 2012, 53: 399-402). Although this method has the characteristics of cheap catalyst, green reaction solvent and easy operation, it also has the disadvantages of serious acid wastewater pollution and complex product purification. Based on this, Firouzeh Nemati et al. still used water as the reaction solvent and adopted Fe3O4@SiO2-SO3H as a heterogeneous catalyst, which can effectively reduce the reaction time and improve the yield of the reaction product (Nano-Fe3O4 encapsulated-silicap articles bearing sulfonic acid groups as a magnetically separable catalyst for green and efficient synthesis of functionalized pyrimido[4,5-b]quinolinesand indeno fused pyrido[2,3-d]pyrimidines in water[J], Chinese Chemical Letters, 2013, 24: 370-372). However, this method also has the disadvantages of complex catalyst preparation process and low number of recycling times.

[0004] Acidic ionic liquids have been used as catalysts to catalyze the preparation of pyrimido[4,5-b]quinoline derivatives due to their advantages of low melting point, low volatility, designable structure and acidity, simple post-treatment, recyclability and simple preparation. For example, Farhad Shirini et al. used ethanol as a reaction solvent and an acidic ionic liquid containing imidazole and disulfonate as a catalyst to prepare a series of pyrimido[4,5-b]quinoline derivatives. This method has the advantages of high yield, short reaction time and simple operation process. The catalyst can be recycled three times after dehydration, and its catalytic efficiency is not significantly reduced (1,3-Disulfonic acid imidazolium hydrogen sulfate: a reusable and efficient ionic liquid for the one-pot multi-component synthesis of pyrimido[4,5-b]quinoline derivatives [J], RSC Advances, 2015, 5: 23586-23590). However, since the parent structure of the above-mentioned catalyst is a difficult-to-biodegrade imidazole structure, the preparation price is high and the usage is large, Yue Caibo and others from Anhui University of Technology used a non-imidazolyl acidic ionic liquid containing three sulfonate groups with higher acidity as a catalyst, which reduced the amount of catalyst used and increased the number of catalyst recycling times (A method for preparing pyrimido[4,5-b]quinoline derivatives catalyzed by acidic ionic liquids [P], application number: 201510848209.8).

[0005] However, the above methods still have the problems of complex catalyst preparation process and environmental pollution. For example, the preparation of acidic ionic liquids themselves often requires a two-step synthesis method, and volatile organic solvents need to be used in the preparation process, which increases the preparation cost and also causes environmental pollution. In addition, the purification steps of acidic ionic liquids are numerous and difficult.

[0006] The low eutectic solvent is composed of a hydrogen bond acceptor and a hydrogen bond donor or a quaternary ammonium salt and a metal salt. It is considered to be a substitute for a new generation of ionic liquids. The preparation process of the low eutectic solvent is simple and the cost is low. In addition, it has the advantages of biodegradability, non-toxicity, and non-volatile. Therefore, the low eutectic solvent can be used as a catalyst and reaction solvent in the preparation process of pharmaceutical intermediates. Therefore, the present invention intends to propose a method of using a low eutectic solvent to replace an acidic ionic liquid as a catalyst and reaction solvent to catalyze the three-component reaction of an aromatic aldehyde, a 6-aminouracil derivative and a 1,3-cyclohexanedione derivative to prepare a pyrimido[4,5-b]quinolinone derivative, in order to obtain the purpose of economically efficient, safe, environmentally friendly, and continuous preparation of a pharmaceutical intermediate pyrimido[4,5-b]quinolinone derivative. Summary of the invention

[0007] In view of the problems in the prior art, the present invention provides a method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative by catalysis using a low eutectic solvent, thereby solving the problems of the catalytic system used in the prior art in preparing pyrimido[4,5-b]quinolinone derivatives, such as being toxic and harmful, not easily biodegradable, having poor economic efficiency, not easily regenerated, and serious environmental pollution caused by the large amount of reaction solvent used.

[0008] The purpose of the present invention can be achieved through the following technical solutions:

[0009] A method for preparing a drug intermediate pyrimido[4,5-b]quinoline derivative by catalysis of a deep eutectic solvent, wherein the preparation method uses an aromatic aldehyde, a 6-aminouracil derivative and a 1,3-cyclohexanedione derivative as reaction raw materials, uses a deep eutectic solvent as a catalyst, and is prepared under heating conditions;

[0010] The chemical reaction formula involved in the preparation method of the drug intermediate pyrimido[4,5-b]quinoline derivative is:

[0011]

[0012] The 6-aminouracil derivative is 6-aminouracil or 6-amino-1,3-dimethyluracil;

[0013] The aromatic aldehyde is any one of benzaldehyde, p-chlorobenzaldehyde, p-bromobenzaldehyde, p-tolualdehyde, p-methoxybenzaldehyde, p-hydroxybenzaldehyde, o-chlorobenzaldehyde, o-nitrobenzaldehyde, m-nitrobenzaldehyde, 2,4-dichlorobenzaldehyde, 3,4-dichlorobenzaldehyde, and 3,4-dimethylbenzaldehyde;

[0014] The 1,3-cyclohexanedione derivative is 1,3-cyclohexanedione or 5,5-dimethyl-1,3-cyclohexanedione.

[0015] Preferably, the preparation method comprises the following steps:

[0016] Step 1: catalytic reaction, adding an aromatic aldehyde, a 6-aminouracil derivative and a 1,3-cyclohexanedione derivative in a preset molar ratio as reaction raw materials into a flask containing a preset amount of a low eutectic solvent, heating the mixture to a preset temperature in an oil bath under magnetic stirring, and then keeping the temperature to react until the aromatic aldehyde disappears, followed by hot filtration, and the filter residue is naturally cooled to room temperature and then washed with anhydrous ethanol and then vacuum dried to obtain a pyrimido[4,5-b]quinolinone derivative, detecting its purity by high performance liquid chromatography, and calculating the yield;

[0017] Step 2: Recycling the catalyst, the filtrate after filtering in step 1 is immediately added with a preset molar ratio of 6-aminouracil derivative, aromatic aldehyde and 1,3-cyclohexanedione derivative without any treatment, and the catalytic reaction is carried out according to the operation of step 1, and the operation is repeated for multiple times;

[0018] Step 3: Catalyst regeneration. When the catalyst cannot meet the preset use conditions after multiple cycles of use, add a preset volume of petroleum ether to the catalyst that cannot be recycled, stir for 30 minutes, then separate the liquids, collect the lower layer of liquid, then add the same volume of petroleum ether, continue stirring for 30 minutes, then separate the liquids, collect the lower layer of liquid, perform a total of three washing operations, and vacuum dry the lower layer of liquid obtained for the third time at 85°C for 8 hours to obtain a regenerated catalyst.

[0019] Preferably, the pyrimido[4,5-b]quinolinone derivative obtained in each cycle is subjected to purity detection and yield calculation. When the purity is lower than 98% or the yield decreases by more than 5%, the recycling of the catalyst is stopped.

[0020] Preferably, the molar ratio of the 6-aminouracil derivative, the aromatic aldehyde and the 1,3-cyclohexanedione derivative in the catalytic reaction is 1:1:1.

[0021] Preferably, the low eutectic solvent in the catalytic reaction is obtained by heating caprolactam and p-toluenesulfonic acid, wherein the molar ratio of caprolactam to p-toluenesulfonic acid is 1:(1-4), preferably 1:3.

[0022] Preferably, the usage mass of the deep eutectic solvent in grams is 6 to 11 times, preferably 7 to 9 times, the molar amount of the aromatic aldehyde in millimoles.

[0023] Preferably, the temperature of the heating and insulation reaction in the catalytic reaction is 50-90°C, preferably 57-75°C.

[0024] Preferably, the heat preservation reaction time in the catalytic reaction is 34 to 46 minutes.

[0025] Preferably, petroleum ether with a boiling range of 60 to 90° C. is used in the catalyst regeneration, and its volume usage in milliliters is 2 to 4 times the mass of the low eutectic solvent in grams.

[0026] Beneficial effects of the present invention:

[0027] The invention discloses a method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinolinone derivative by catalysis of a deep eutectic solvent, wherein aromatic aldehyde, 6-aminouracil derivative and 1,3-cyclohexanedione derivative are used as reaction raw materials, and a deep eutectic solvent composed of caprolactam and p-toluenesulfonic acid is used as a reaction solvent and catalyst to prepare the pyrimido[4,5-b]quinolinone derivative by condensation reaction. The method has the advantages of simple catalyst preparation, high recycling times, renewability, high economic efficiency, low environmental pollution, etc. In addition, the product pyrimido[4,5-b]quinolinone derivative is easy to separate and simple to purify, and can easily realize industrial large-scale and continuous production. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to facilitate understanding by those skilled in the art, the present invention is further described below with reference to the accompanying drawings.

[0029] Figure 1 8,8-dimethyl-5-phenyl-5,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 7H) -trione prepared in Example 1 of the present invention 1 H NMR nuclear magnetic resonance spectrum.

[0030] Figure 2 The 8,8-dimethyl-5-(2-nitrophenyl)-5,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 7H) -trione prepared in Example 3 of the present invention is 1 H NMR nuclear magnetic resonance spectrum. DETAILED DESCRIPTION

[0031] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] The following examples show that the structures of the reaction products pyrimido[4,5-b]quinolinone derivatives were characterized by using an AVANCE II 400MHz nuclear magnetic resonance spectrometer from Bruker, Germany, and an EQUINOX 55 infrared spectrometer (KBr pellet) from Bruker, Germany, for hydrogen nuclear magnetic resonance spectroscopy.

[0033] The purity of the reaction product pyrimido[4,5-b]quinolinone derivative was characterized by using a high performance liquid chromatograph model Water 2695 from Waters Corporation of the United States.

[0034] The low eutectic solvent used in the present invention is prepared by mixing caprolactam and p-toluenesulfonic acid and heating them. The specific preparation process is referred to in the relevant literature (C6H 11 Preparation of NO / 2TsOH type low eutectic solvent and its catalytic oxidation desulfurization performance [J], Acta Petrolei Sinica (Petroleum Processing), 2019, 35(4): 775-782): Add caprolactam and p-toluenesulfonic acid in a certain amount ratio into a three-necked flask with a condenser and a thermometer, heat to 130°C in an oil bath under mechanical stirring and maintain this temperature until a viscous liquid is obtained, and then vacuum dry at 85°C for 12h to obtain the low eutectic solvent required by the present invention.

[0035] A method for preparing a drug intermediate pyrimido[4,5-b]quinoline derivative by catalysis of a deep eutectic solvent, wherein the preparation method uses an aromatic aldehyde, a 6-aminouracil derivative and a 1,3-cyclohexanedione derivative as reaction raw materials, uses a deep eutectic solvent as a catalyst, and is prepared under heating conditions;

[0036] The chemical reaction formula involved in the preparation method of the drug intermediate pyrimido[4,5-b]quinoline derivative is:

[0037]

[0038] The 6-aminouracil derivative is 6-aminouracil or 6-amino-1,3-dimethyluracil;

[0039] The aromatic aldehyde is any one of benzaldehyde, p-chlorobenzaldehyde, p-bromobenzaldehyde, p-tolualdehyde, p-methoxybenzaldehyde, p-hydroxybenzaldehyde, o-chlorobenzaldehyde, o-nitrobenzaldehyde, m-nitrobenzaldehyde, 2,4-dichlorobenzaldehyde, 3,4-dichlorobenzaldehyde, and 3,4-dimethylbenzaldehyde;

[0040] The 1,3-cyclohexanedione derivative is 1,3-cyclohexanedione or 5,5-dimethyl-1,3-cyclohexanedione.

[0041] As a technical optimization solution of the present invention, the preparation method comprises the following steps:

[0042] Step 1: catalytic reaction, adding an aromatic aldehyde, a 6-aminouracil derivative and a 1,3-cyclohexanedione derivative in a preset molar ratio as reaction raw materials into a flask containing a preset amount of a low eutectic solvent, heating the mixture to a preset temperature in an oil bath under magnetic stirring, and then keeping the temperature to react until the aromatic aldehyde disappears, followed by hot filtration, and the filter residue is naturally cooled to room temperature and then washed with anhydrous ethanol and then vacuum dried to obtain a pyrimido[4,5-b]quinolinone derivative, detecting its purity by high performance liquid chromatography, and calculating the yield;

[0043] Step 2: Recycling the catalyst, the filtrate after filtering in step 1 is immediately added with a preset molar ratio of 6-aminouracil derivative, aromatic aldehyde and 1,3-cyclohexanedione derivative without any treatment, and the catalytic reaction is carried out according to the operation of step 1, and the operation is repeated for multiple times;

[0044] Step 3: Catalyst regeneration. When the catalyst cannot meet the preset use conditions after multiple cycles of use, add a preset volume of petroleum ether to the catalyst that cannot be recycled, stir for 30 minutes, then separate the liquids, collect the lower layer of liquid, then add the same volume of petroleum ether, continue stirring for 30 minutes, then separate the liquids, collect the lower layer of liquid, perform a total of three washing operations, and vacuum dry the lower layer of liquid obtained for the third time at 85°C for 8 hours to obtain a regenerated catalyst.

[0045] As a technical optimization scheme of the present invention, the pyrimido[4,5-b]quinolinone derivative obtained in each cycle is subjected to purity detection and yield calculation. When the purity is lower than 98% or the yield decreases by more than 5%, the recycling of the catalyst is stopped.

[0046] As a technical optimization scheme of the present invention, the molar ratio of the 6-aminouracil derivative, the aromatic aldehyde and the 1,3-cyclohexanedione derivative in the catalytic reaction is 1:1:1.

[0047] As a technical optimization scheme of the present invention, the low eutectic solvent in the catalytic reaction is obtained by heating caprolactam and p-toluenesulfonic acid, wherein the molar ratio of caprolactam to p-toluenesulfonic acid is 1:(1-4), preferably 1:3.

[0048] As a technical optimization solution of the present invention, the usage mass of the low eutectic solvent in grams is 6 to 11 times, preferably 7 to 9 times, the molar amount of the aromatic aldehyde in millimoles.

[0049] As a technical optimization solution of the present invention, the temperature of the heating and insulation reaction in the catalytic reaction is 50-90°C, preferably 57-75°C.

[0050] As a technical optimization solution of the present invention, the heat preservation reaction time in the catalytic reaction is 34 to 46 minutes.

[0051] As a technical optimization scheme of the present invention, petroleum ether with a boiling range of 60 to 90° C. is used in the catalyst regeneration, and its volume usage in milliliters is 2 to 4 times the mass of the low eutectic solvent in grams.

[0052] The present invention is further described below in conjunction with specific embodiments.

[0053] Example 1

[0054] Preparation of 8,8-dimethyl-5-phenyl-5,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,7H)-trione

[0055]

[0056] At room temperature, 6-aminouracil (1.0mmol, 0.13g), benzaldehyde (1.0mmol, 0.11g) and 5,5-dimethyl-1,3-cyclohexanedione (1.0mmol, 0.14g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 7g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 59°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 34min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The residue was naturally cooled to room temperature and then washed with anhydrous ethanol for 3 times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.32g of crystals. The crystal product is determined to be 8,8-dimethyl-5-phenyl-5,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 7H) -trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 8,8-dimethyl-5-phenyl-5,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 7H) -trione in the crystal is determined to be 99.5% by high performance liquid chromatography internal standard method; finally, the yield of 8,8-dimethyl-5-phenyl-5,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 7H) -trione is calculated to be 93%.

[0057] The filtrate obtained by suction filtration can be directly added with 6-aminouracil, benzaldehyde and 5,5-dimethyl-1,3-cyclohexanedione without any treatment and then recycled.

[0058] Product characterization: 1H NMR (400MHz, DMSO-d6): δ=10.73 (s, 1H), 10.22 (s, 1H), 8.79 (s, 1H), 7.19 (d, J=4.3Hz, 4H), 7.12~7.05 (m, 1H), 4.75 (s, 1H), 2.46 (d, J= 12.2Hz, 2H), 2.21 (d, J=16.1Hz, 1H), 2.02 (d, J=16.1Hz, 1H), 1.03 (s, 3H), 0.89 (s, 3H)ppm; IR (KBr): ν=3403, 3254, 3187, 2935, 1651cm -1 .

[0059] Example 2

[0060] Preparation of 5-(4-methoxyphenyl)-8,8-dimethyl-5,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,7H)-trione

[0061]

[0062] At room temperature, 6-aminouracil (1.0mmol, 0.13g), p-methoxybenzaldehyde (1.0mmol, 0.14g) and 5,5-dimethyl-1,3-cyclohexanedione (1.0mmol, 0.14g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 8g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 64°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 39min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The residue was naturally cooled to room temperature and then washed with anhydrous ethanol 4 times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.33g of crystals. The crystal product is determined to be 5-(4-methoxyphenyl)-8,8-dimethyl-5,8,9,10-tetrahydropyrimidine [4,5-b]quinoline-2,4,6 (1H, 3H, 7H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 5-(4-methoxyphenyl)-8,8-dimethyl-5,8,9,10-tetrahydropyrimidine [4,5-b]quinoline-2,4,6 (1H, 3H, 7H)-trione in the crystal is determined to be 99.1% by high performance liquid chromatography internal standard method; finally, the yield of 5-(4-methoxyphenyl)-8,8-dimethyl-5,8,9,10-tetrahydropyrimidine [4,5-b]quinoline-2,4,6 (1H, 3H, 7H)-trione is calculated to be 90%.

[0063] The filtrate obtained by suction filtration can be directly added with 6-aminouracil, p-methoxybenzaldehyde and 5,5-dimethyl-1,3-cyclohexanedione without any treatment and then recycled.

[0064] Product characterization: 1 H NMR (400MHz, DMSO-d6): δ=10.72 (s, 1H), 10.20 (s, 1H), 8.69 (s, 1H), 7.06 (d, J=8.8Hz, 2H), 6.78 (d, J=11.8Hz, 2H), 4.65 (s, 1H), 3. 32 (s, 3H), 2.43 (d, J = 14.5Hz, 2H), 2.15 (d, J = 14.5Hz, 2H), 1.04 (s, 3H), 0.88 (s, 3H) ppm; IR (KBr): ν = 3406, 3251, 3197, 2931, 1655cm -1 .

[0065] Example 3

[0066] Preparation of 8,8-dimethyl-5-(2-nitrophenyl)-5,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,7H)-trione

[0067]

[0068] At room temperature, 6-aminouracil (1.0mmol, 0.13g), o-nitrobenzaldehyde (1.0mmol, 0.15g) and 5,5-dimethyl-1,3-cyclohexanedione (1.0mmol, 0.14g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 7g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 61°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 37min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The residue was naturally cooled to room temperature and washed with anhydrous ethanol three times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.36g of crystals. The crystal product is determined to be 8,8-dimethyl-5-(2-nitrophenyl)-5,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 7H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 8,8-dimethyl-5-(2-nitrophenyl)-5,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 7H)-trione in the crystal is determined to be 99.2% by high performance liquid chromatography internal standard method; finally, the yield of 8,8-dimethyl-5-(2-nitrophenyl)-5,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 7H)-trione is calculated to be 86%.

[0069] The filtrate obtained by suction filtration can be directly added with 6-aminouracil, o-nitrobenzaldehyde and 5,5-dimethyl-1,3-cyclohexanedione without any treatment and then recycled.

[0070] Product characterization: 1 H NMR (400MHz, DMSO-d6): δ=10.68 (s, 1H), 10.38 (s, 1H), 8.88 (s, 1H), 7.74 (d, J=7.3Hz, 2H), 7.50~7.60 (m, 2H), 7.30~7.34 (m, 1H), 4.96 (s, 1H), 2.16 (s, 2H), 1.98 (s, 2H), 1.02 (s, 3H), 0.88 (s, 3H)ppm; IR (KBr): ν = 3409, 3257, 3194, 2933, 1658cm -1 .

[0071] Example 4

[0072] Preparation of 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,5H)-trione

[0073]

[0074] At room temperature, 6-amino-1,3-dimethyluracil (1.0mmol, 0.16g), p-chlorobenzaldehyde (1.0mmol, 0.14g) and 5,5-dimethyl-1,3-cyclohexanedione (1.0mmol, 0.14g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 9g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 71°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 36min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The residue was naturally cooled to room temperature and then washed with anhydrous ethanol for 3 times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.35g of crystals. The crystal product is determined to be 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione in the crystal is determined to be 99.4% by high performance liquid chromatography internal standard method; finally, the yield of 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione is calculated to be 88%.

[0075] The filtrate obtained by suction filtration can be directly added with 6-amino-1,3-dimethyluracil, p-chlorobenzaldehyde and 5,5-dimethyl-1,3-cyclohexanedione without any treatment and then recycled.

[0076] Product characterization: 1H NMR (400MHz, DMSO-d6): δ = 9.03 (br., s, 1H), 7.21 (s, 4H), 4.88 (s, 1H), 3.42 (s, 3H), 3.11 (s, 3H), 2.59 (d, J = 17.4Hz, 1H), 2.57 (d, J = 17.4Hz, 1H), 2.18 (d, J = 16.2Hz, 1H), 2.01 (d, J=16.2Hz, 1H), 1.06 (s, 3H), 0.92 (s, 3H)ppm; IR (KBr): ν=3384, 3042, 2959, 1650, 1629, 1 501, 1378, 1324, 1291, 1244, 1206, 1148, 1089, 1045, 1011, 956, 845, 822, 773, 752, 694cm- 1 .

[0077] Example 5

[0078] Preparation of 5-(4-chlorophenyl)-1,3-dimethyl-7,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,5H)-trione

[0079]

[0080] At room temperature, 6-amino-1,3-dimethyluracil (1.0mmol, 0.16g), p-chlorobenzaldehyde (1.0mmol, 0.14g) and 1,3-cyclohexanedione (1.0mmol, 0.11g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 8g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 67°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 32min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The residue was naturally cooled to room temperature and then washed with anhydrous ethanol for 3 times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.34g of crystals. The crystal product is determined to be 5-(4-chlorophenyl)-1,3-dimethyl-7,8,9,10-tetrahydropyrimidine [4,5-b]quinoline-2,4,6 (1H, 3H, 5H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 5-(4-chlorophenyl)-1,3-dimethyl-7,8,9,10-tetrahydropyrimidine [4,5-b]quinoline-2,4,6 (1H, 3H, 5H)-trione in the crystal is determined to be 99.0% by high performance liquid chromatography internal standard method; finally, the yield of 5-(4-chlorophenyl)-1,3-dimethyl-7,8,9,10-tetrahydropyrimidine [4,5-b]quinoline-2,4,6 (1H, 3H, 5H)-trione is calculated to be 90%.

[0081] The filtrate obtained by suction filtration can be directly added with 6-amino-1,3-dimethyluracil, p-chlorobenzaldehyde and 1,3-cyclohexanedione without any treatment and then recycled.

[0082] Product characterization: 1 H NMR (400MHz, DMSO-d6): δ=9.09 (br., s, 1H), 7.27 (s, 4H), 4.91 (s, 1H), 3.39 (s, 3H), 3 .13(s, 3H), 2.75~2.83(m, 1H), 2.51~2.59(m, 1H), 2.26~2.29(m, 2H), 1.88~1.96(m, 1H) ), 1.75~1.82(m,1H)ppm; IR(KBr): ν3295, 3237, 3089, 2953, 2888, 1697, 1642, 1618, 1 502, 1446, 1379, 1352, 1293, 1260, 1239, 1194, 1172, 1139, 1049, 1008, 947, 839, 748cm -1 .

[0083] Example 6

[0084] Preparation of 1,3,8,8-tetramethyl-5-(4-methyl)-7,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,5H)-trione

[0085]

[0086] At room temperature, 6-amino-1,3-dimethyluracil (1.0mmol, 0.16g), p-methylbenzaldehyde (1.0mmol, 0.12g) and 5,5-dimethyl-1,3-cyclohexanedione (1.0mmol, 0.14g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 9g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 72°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-methylbenzaldehyde disappeared on the thin plate, the required reaction time was 37min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The residue was naturally cooled to room temperature and then washed with anhydrous ethanol for 3 times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.33g of crystals. The crystal product is determined to be 1,3,8,8-tetramethyl-5-(4-methyl)-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 1,3,8,8-tetramethyl-5-(4-methyl)-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione in the crystal is determined to be 99.2% by high performance liquid chromatography internal standard method; finally, the yield of 1,3,8,8-tetramethyl-5-(4-methyl)-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione is calculated to be 85%.

[0087] The filtrate obtained by suction filtration can be directly added with 6-amino-1,3-dimethyluracil, p-methylbenzaldehyde and 5,5-dimethyl-1,3-cyclohexanedione without any treatment and then recycled.

[0088] Product characterization: 1H NMR (400MHz, DMSO-d6): δ=9.01 (br., s, 1H), 7.14 (d, J=8.2Hz, 2H), 6.95 (d, J=8.2Hz, 2H), 4.80 (s, 1H) , 3.48 (s, 3H), 3.10 (s, 3H), 2.56 (d, J = 17.0Hz, 1H), 2.51 (d, J = 17.0Hz, 1H), 2.24 (d, J = 16.2Hz, 1H), 2. 17 (s, 3H), 1.99 (d, J = 16.2Hz, 1H), 1.08 (s, 3H), 0.91 (s, 3H) ppm; IR (KBr): ν = 3224, 3095, 2954, 1698, 1 657, 1644, 1598, 1489, 1380, 1340, 1291, 1247, 1203, 1152, 1126, 1083, 1038, 959, 842, 820, 782, 754cm -1 .

[0089] Example 7

[0090] Preparation of 1,3-dimethyl-5-(4-methyl)-7,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,5H)-trione

[0091]

[0092] At room temperature, 6-amino-1,3-dimethyluracil (1.0mmol, 0.16g), p-methylbenzaldehyde (1.0mmol, 0.12g) and 1,3-cyclohexanedione (1.0mmol, 0.11g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 7g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 69°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 40min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The residue was naturally cooled to room temperature and then washed with anhydrous ethanol for 3 times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.31g of crystals. The crystal product is determined to be 1,3-dimethyl-5-(4-methyl)-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 1,3-dimethyl-5-(4-methyl)-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione in the crystal is determined to be 99.0% by high performance liquid chromatography internal standard method; finally, the yield of 1,3-dimethyl-5-(4-methyl)-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione is calculated to be 86%.

[0093] The filtrate obtained by suction filtration can be directly added with 6-amino-1,3-dimethyluracil, p-methylbenzaldehyde and 1,3-cyclohexanedione without any treatment and then recycled.

[0094] Product characterization: 1 H NMR (400MHz, DMSO-d6): δ=9.07 (br., s, 1H), 7.10 (d, J=8.0Hz, 2H), 6.97 (d, J=8.0Hz, 2H), 4.87 ( s, 1H), 3.45 (s, 3H), 3.09 (s, 3H), 2.74~2.79 (m, 1H), 2.55~2.61 (m, 1H), 2.21~2.27 (m, 2H), 2.19 (s, 3H), 1.91 ~ 1.96 (m, 1H), 1.75 ~ 1.83 (m, 1H) ppm; IR (KBr): ν3287, 3094, 2935, 1699, 1684, 1665 , 1636, 1609, 1504, 1402, 1375, 1356, 1282, 1247, 1206, 1174, 1153, 1129, 1084, 1047, 951, 761cm -1 .

[0095] Example 8

[0096] Preparation of 5-(2-chlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,5H)-trione

[0097]

[0098] At room temperature, 6-amino-1,3-dimethyluracil (1.0mmol, 0.16g), o-chlorobenzaldehyde (1.0mmol, 0.14g) and 5,5-dimethyl-1,3-cyclohexanedione (1.0mmol, 0.14g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 9g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 75°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 39min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The obtained residue was naturally cooled to room temperature and then washed with anhydrous ethanol for 3 times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.33g of crystals. The crystal product is determined to be 5-(2-chlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 5-(2-chlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione in the crystal is determined to be 99.2% by high performance liquid chromatography internal standard method; finally, the yield of 5-(2-chlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione is calculated to be 83%.

[0099] The filtrate obtained by suction filtration can be directly added with 6-amino-1,3-dimethyluracil, o-chlorobenzaldehyde and 5,5-dimethyl-1,3-cyclohexanedione without any treatment and then recycled.

[0100] Product characterization: 1H NMR (400MHz, DMSO-d6): δ=8.97 (br., s, 1H), 7.28 (d, J=7.4Hz, 1H), 7.15~7.21 (m, 2H), 7.07~7.1 1 (m, 1H), 5.19 (s, 1H), 3.49 (s, 3H), 3.02 (s, 3H), 2.55 (d, J = 17.0Hz, 2H), 2.14 (d, J = 15.8Hz, 1H), 1.94 (d, J=15.8Hz, 1H), 1.06 (s, 3H), 0.90 (s, 3H)ppm; IR (KBr): ν=3219, 3088, 2956, 1698, 1657, 1 634, 1609, 1490, 1435, 1383, 1362, 1286, 1241, 1206, 1147, 1123, 1076, 1046, 959, 838, 771, 754cm -1 .

[0101] Example 9

[0102] Preparation of 6-(2,4-dichlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,5H)-trione

[0103]

[0104] At room temperature, 6-amino-1,3-dimethyluracil (1.0mmol, 0.16g), 2,4-dichlorobenzaldehyde (1.0mmol, 0.18g) and 5,5-dimethyl-1,3-cyclohexanedione (1.0mmol, 0.14g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer, and then the temperature was uniformly raised to 59°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction time was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 46min. Heating and stirring were stopped immediately and the filter was filtered while hot. The obtained filter residue was naturally cooled to room temperature and washed with anhydrous ethanol 3 times. Finally, it was vacuum dried at 80°C to constant weight to obtain 0.40g crystals. The crystal product is determined to be 5-(2,4-dichlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 5-(2,4-dichlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione in the crystal is determined to be 99.3% by high performance liquid chromatography internal standard method; finally, the yield of 5-(2,4-dichlorophenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione is calculated to be 92%.

[0105] The filtrate obtained by suction filtration can be directly added with 6-amino-1,3-dimethyluracil, 2,4-dichlorobenzaldehyde and 5,5-dimethyl-1,3-cyclohexanedione without any treatment and then recycled.

[0106] Product characterization: 1H NMR (400MHz, DMSO-d6): δ=9.06 (br., s, 1H), 7.34 (d, J=2.0Hz, 1H), 7.30 (d, J=8.2Hz, 1H), 7.21 (dd, J1=2 .0Hz, J2=8.2Hz, 1H), 5.09(s, 1H), 3.47(s, 3H), 3.01(s, 3H), 2.48(d, J=17.2Hz, 2H), 2.22(d, J=15.8Hz, 1 H), 1.96 (d, J=15.8Hz, 1H), 1.02 (s, 3H), 0.86 (s, 3H)ppm; IR (KBr): ν=3223, 3090, 2950, ​​2868, 1700, 1651 , 1642, 1598, 1493, 1453, 1380, 1354, 1283, 1239, 1209, 1146, 1127, 1097, 1085, 1042, 964, 859, 840, 751cm -1 .

[0107] Example 10

[0108] Preparation of 5-(3,4-dimethylphenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidin[4,5-b]quinoline-2,4,6(1H,3H,5H)-trione

[0109]

[0110] At room temperature, 6-amino-1,3-dimethyluracil (1.0mmol, 0.16g), 3,4-dimethylbenzaldehyde (1.0mmol, 0.13g) and 5,5-dimethyl-1,3-cyclohexanedione (1.0mmol, 0.14g) were added to a 50mL three-necked flask with a magnetic stirrer, a spherical condenser and a thermometer to which 8g of a low eutectic solvent (the molar ratio of caprolactam to p-toluenesulfonic acid was 1:3) had been added. Then, the mixture was uniformly heated to 57°C in a magnetic stirring and methyl silicone oil bath and maintained at this temperature. The reaction was monitored by TLC (thin plate chromatography). When the point of the raw material p-chlorobenzaldehyde disappeared on the thin plate, the required reaction time was 34min. Heating and stirring were stopped immediately and the mixture was filtered while hot. The residue was naturally cooled to room temperature and then washed with anhydrous ethanol 4 times. Finally, the residue was vacuum dried at 80°C to constant weight to obtain 0.35g of crystals. The crystal product is determined to be 5-(3,4-dimethylphenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione by hydrogen nuclear magnetic resonance spectrum and infrared spectrum analysis; the purity of 5-(3,4-dimethylphenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione in the crystal is determined to be 99.1% by high performance liquid chromatography internal standard method; finally, the yield of 5-(3,4-dimethylphenyl)-1,3,8,8-tetramethyl-7,8,9,10-tetrahydropyrimidine [4,5-b] quinoline-2,4,6 (1H, 3H, 5H)-trione is calculated to be 89%.

[0111] The filtrate obtained by suction filtration can be directly added with 6-amino-1,3-dimethyluracil, 3,4-dimethylbenzaldehyde and 5,5-dimethyl-1,3-cyclohexanedione without any treatment and then recycled.

[0112] Product characterization: 1H NMR (400MHz, DMSO-d6): δ=9.01 (br., s, 1H), 7.00 (s, 1H), 6.91~6.96 (m, 2H), 4.79 (s, 1H), 3.41 (s, 3H) ), 3.10 (s, 3H), 2.64 (d, J = 17.2Hz, 1H), 2.55 (d, J = 17.2Hz, 1H), 2.19 (d, J = 16.6Hz, 1H), 2.14 (s, 3H), 2 .11 (s, 3H), 2.06 (d, J = 16.6Hz, 1H), 1.07 (s, 3H), 0.93 (s, 3H) ppm; IR (KBr): ν = 3207, 3084, 2958, 1702, 1659, 1640, 1596, 1490, 1381, 1293, 1248, 1212, 1152, 1127, 1085, 1056, 967, 891, 840, 794, 758, 691cm -1 .

[0113] Examples 11 to 15

[0114] Feasibility of recycling deep eutectic solvents

[0115] Example 1 was used as a probe experiment to conduct a feasibility test for recycling the low eutectic solvent. The specific experimental process and detection method were the same as in Example 1, except that the low eutectic solvent used was the filtrate in Example 1. Four recycling experiments were conducted under the same conditions, and the results are shown in Table 1.

[0116] Table 1

[0117]

[0118] From the data in the above table, it can be seen that as the number of times the deep eutectic solvent is recycled increases, the catalytic ability decreases due to the reduction in the amount of catalyst and the superposition of the content of by-products dissolved therein, resulting in a decrease in the purity and yield of the product. For economic considerations, when the liquid chromatography purity of the product is lower than 98% or the yield decreases by more than 5%, the deep eutectic solvent should not be recycled and needs to be regenerated.

[0119] Example 16

[0120] Regeneration of deep eutectic solvents

[0121] The low eutectic solvent of Example 15 that has been recycled 4 times was used as a probe experiment to conduct a regeneration test of the low eutectic solvent: 20 ml of petroleum ether (boiling range of 60-90° C.) was added to the filtrate of Example 15 that stopped recycling, stirred for 30 minutes, then separated, and the lower layer of liquid was collected, and then 20 ml of petroleum ether (boiling range of 60-90° C.) was added thereto, and continued stirring for 30 minutes, and then separated, and the lower layer of liquid was collected, and a total of three washing operations were performed. The lower layer of liquid obtained for the third time was vacuum dried at 85° C. for 8 hours to obtain the regenerated low eutectic solvent.

[0122] Examples 17 to 20

[0123] Feasibility of recycling the regenerated deep eutectic solvent

[0124] Example 1 was used as a probe experiment to conduct a feasibility test for recycling the regenerated deep eutectic solvent. The specific experimental process and detection method were the same as those of Examples 11 to 15, except that the regenerated deep eutectic solvent in Example 16 was used. Three recycling experiments were conducted under the same conditions, and the results are shown in Table 2.

[0125] Table 2

[0126]

[0127] From the data in the above table, it can be seen that the regenerated deep eutectic solvent can still be recycled, and the law of the recycling process is the same as that of the fresh deep eutectic solvent, that is, as the number of recycling times increases, the purity and yield of the product decrease. For economic considerations, when the liquid chromatography purity of the product is lower than 98% or the yield decreases by more than 5%, the deep eutectic solvent should not be recycled and needs to be regenerated again.

[0128] Examples 21 to 25

[0129] Feasibility of recycling deep eutectic solvents

[0130] Example 7 was used as a probe experiment to conduct a feasibility test for recycling the low eutectic solvent. The specific experimental process and detection method were the same as in Example 7, except that the low eutectic solvent used was the filtrate in Example 7. Four recycling experiments were conducted under the same conditions, and the results are shown in Table 3.

[0131] Table 3

[0132]

[0133] From the data in the above table, it can be seen that as the number of times the deep eutectic solvent is recycled increases, the catalytic ability decreases due to the reduction in the amount of catalyst and the superposition of the content of by-products dissolved therein, resulting in a decrease in the purity and yield of the product. For economic considerations, when the liquid chromatography purity of the product is lower than 98% or the yield decreases by more than 5%, the deep eutectic solvent should not be recycled and needs to be regenerated.

[0134] Embodiment 26

[0135] Regeneration of deep eutectic solvents

[0136] The low eutectic solvent of Example 25 that has been recycled 4 times was used as a probe experiment to conduct a regeneration test of the low eutectic solvent: 18 ml of petroleum ether (boiling range of 60-90° C.) was added to the filtrate of Example 25 that stopped recycling, stirred for 30 minutes, then separated, and the lower layer of liquid was collected, and then 18 ml of petroleum ether (boiling range of 60-90° C.) was added thereto, and continued stirring for 30 minutes, and then separated, and the lower layer of liquid was collected, and a total of three washing operations were performed. The lower layer of liquid obtained for the third time was vacuum dried at 85° C. for 8 hours to obtain the regenerated low eutectic solvent.

[0137] Examples 27 to 30

[0138] Feasibility of recycling the regenerated deep eutectic solvent

[0139] Example 7 was used as a probe experiment to conduct a feasibility test for recycling the regenerated deep eutectic solvent. The specific experimental process and detection method were the same as those of Examples 21 to 25, except that the regenerated deep eutectic solvent in Example 26 was used. Three recycling experiments were conducted under the same conditions, and the results are shown in Table 4.

[0140] Table 4

[0141]

[0142] From the data in the above table, it can be seen that the regenerated deep eutectic solvent can still be recycled, and the law of the recycling process is the same as that of the fresh deep eutectic solvent, that is, as the number of recycling times increases, the purity and yield of the product decrease. For economic considerations, when the liquid chromatography purity of the product is lower than 98% or the yield decreases by more than 5%, the deep eutectic solvent should not be recycled and needs to be regenerated again.

[0143] The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific embodiments described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.

Claims

1. A method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent, It is characterized in that The preparation method uses aromatic aldehyde, 6-aminouracil derivative and 1,3-cyclohexanedione derivative as reaction raw materials, uses a low eutectic solvent as a catalyst, and is prepared under heating conditions. The chemical reaction formula involved in the preparation method of the drug intermediate pyrimido[4,5-b]quinoline derivative is: The 6-aminouracil derivative is 6-aminouracil or 6-amino-1,3-dimethyluracil; The aromatic aldehyde is any one of benzaldehyde, p-chlorobenzaldehyde, p-bromobenzaldehyde, p-tolualdehyde, p-methoxybenzaldehyde, p-hydroxybenzaldehyde, o-chlorobenzaldehyde, o-nitrobenzaldehyde, m-nitrobenzaldehyde, 2,4-dichlorobenzaldehyde, 3,4-dichlorobenzaldehyde, and 3,4-dimethylbenzaldehyde; The 1,3-cyclohexanedione derivative is 1,3-cyclohexanedione or 5,5-dimethyl-1,3-cyclohexanedione.

2. The method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent according to claim 1, It is characterized in that The preparation method comprises the following steps: Step 1: catalytic reaction, adding an aromatic aldehyde, a 6-aminouracil derivative and a 1,3-cyclohexanedione derivative in a preset molar ratio as reaction raw materials into a flask containing a preset amount of a low eutectic solvent, heating the mixture to a preset temperature in an oil bath under magnetic stirring, and then keeping the temperature to react until the aromatic aldehyde disappears, followed by hot filtration, and the filter residue is naturally cooled to room temperature and then washed with anhydrous ethanol and then vacuum dried to obtain a pyrimido[4,5-b]quinolinone derivative, detecting its purity by high performance liquid chromatography, and calculating the yield; Step 2: Recycling the catalyst, the filtrate after filtering in step 1 is immediately added with a preset molar ratio of 6-aminouracil derivative, aromatic aldehyde and 1,3-cyclohexanedione derivative without any treatment, and the catalytic reaction is carried out according to the operation of step 1, and the operation is repeated for multiple times; Step 3: Catalyst regeneration. When the catalyst cannot meet the preset use conditions after multiple cycles of use, add a preset volume of petroleum ether to the catalyst that cannot be recycled, stir for 30 minutes, then separate the liquids, collect the lower layer of liquid, then add the same volume of petroleum ether, continue stirring for 30 minutes, then separate the liquids, collect the lower layer of liquid, perform a total of three washing operations, and vacuum dry the lower layer of liquid obtained for the third time at 85°C for 8 hours to obtain a regenerated catalyst.

3. The method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent according to claim 2, It is characterized in that The pyrimido[4,5-b]quinolinone derivatives obtained in each cycle are subjected to purity detection and yield calculation. When the purity is lower than 98% or the yield decreases by more than 5%, the recycling of the catalyst is stopped.

4. The method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent according to claim 2, It is characterized in that In the catalytic reaction, the molar ratio of the 6-aminouracil derivative, the aromatic aldehyde and the 1,3-cyclohexanedione derivative is 1:1:

1.

5. The method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent according to claim 4, It is characterized in that The low eutectic solvent in the catalytic reaction is obtained by heating caprolactam and p-toluenesulfonic acid, wherein the molar ratio of caprolactam to p-toluenesulfonic acid is 1:(1-4), preferably 1:

3.

6. The method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent according to claim 5, It is characterized in that The usage mass of the deep eutectic solvent in grams is 6 to 11 times, preferably 7 to 9 times, the molar amount of the aromatic aldehyde in millimoles.

7. The method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent according to claim 2, It is characterized in that The temperature of the heating and insulation reaction in the catalytic reaction is 50-90°C, preferably 57-75°C.

8. The method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent according to claim 2, It is characterized in that The heat preservation reaction time in the catalytic reaction is 34 to 46 minutes.

9. The method for preparing a pharmaceutical intermediate pyrimido[4,5-b]quinoline derivative catalyzed by a deep eutectic solvent according to claim 2, It is characterized in that The catalyst regeneration uses petroleum ether with a boiling range of 60 to 90° C., and its volume usage in milliliters is 2 to 4 times the mass of the low eutectic solvent in grams.